SAN DIEGO, CA, USA I June 30, 2025 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

MONTPELLIER, France I July 01, 2025 I Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of ...

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore. Preliminary data from an ongoing dose-escalation study of IKS014 has shown ...

BRISBANE, CA, USA I June 30, 2025 I Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi ...

Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement ...

Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was ...

CAMBRIDGE, MA, USA I June 30, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 ...

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to minimize the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...

Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET ...

BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, ...

TOKYO, Japan I June 30, 2025 I Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, ...

NORTH CHICAGO, IL and SAN DIEGO, CA, USA I June 30, 2025 I AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology ...